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A B S T R A C T
Redox regulation has been proposed to control various aspects of carcinogenesis, cancer cell growth, metabo-
lism, migration, invasion, metastasis and cancer vascularization. As cancer has many faces, the role of redox
control in diﬀerent cancers and in the numerous cancer-related processes often point in diﬀerent directions. In
this review, we focus on the redox control mechanisms of tumor cell destruction. The review covers the tumor-
intrinsic role of oxidants derived from the reduction of oxygen and nitrogen in the control of tumor cell pro-
liferation as well as the roles of oxidants and antioxidant systems in cancer cell death caused by traditional
anticancer weapons (chemotherapeutic agents, radiotherapy, photodynamic therapy). Emphasis is also put on
the role of oxidants and redox status in the outcome following interactions between cancer cells, cytotoxic
lymphocytes and tumor inﬁltrating macrophages.
1. Introduction
Cancer represents the toughest challenge for modern medicine and
is responsible for approximately 9 million deaths worldwide with more
than 14 million new cases reported each year [1,2]. Therefore, under-
standing formation and spreading of cancer as well as mechanisms for
developing therapy resistance are of crucial importance for the devel-
opment of new eﬀective treatments.
Most aspects of cancer biology display some degree of redox reg-
ulation. Carcinogenesis, cancer cell proliferation, migration, invasion,
metastasis and vascularization all appear to be under redox control.
Moreover, inﬂammatory cells in the tumor microenvironment may
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produce superoxide, hydrogen peroxide and nitric oxide which impacts
on both the cancer cells and the neighboring regulatory or eﬀector
immune cells. Many of these aspects of cancer biology have been ex-
tensively reviewed and therefore this paper focuses on the redox control
of cancer cell destruction. Killing the cancer cells is the ultimate goal of
both traditional therapies such as chemotherapy and ionizing radiation
and of biological therapies such as checkpoint inhibitors (e.g. anti-PD1
and anti-CTLA-4 antibodies) [3], anticancer antibodies (e.g. against
EGFR or Her antigens) [4,5] and adoptive cell therapies (e.g. with NK
cells, cytotoxic T lymphocytes, T cells expressing chimeric antigen re-
ceptors; CAR-T cells) [6,7]. Other targeted treatment modalities; e.g.,
inhibitors of tumor vascularization (VEGF pathway inhibitors), tyrosine
kinase inhibitors, hormone therapy indirectly also result in tumor cell
death [8].
Redox control is known to aﬀect the biology of tumors at multiple
levels:
a) Redox signaling has a great impact on tumor cell proliferation.
Signals through growth factor receptors (GFR) as well as integrins
stimulate production of superoxide (O2.-), which dismutates to hy-
drogen peroxide (H2O2) or production of H2O2, directly. These
oxidants are produced by NADPH oxidases (NOXs) that are acti-
vated via largely overlapping pathways [9]. Stimulation of GFRs
(e.g. epidermal GFR, insulin-like GFR, transforming GFR beta, pla-
telet-derived GFR) by their speciﬁc growth hormones or ligation of
integrins by extracellular matrix components trigger the Ras-Raf-Erk
and the PI3K-Akt signaling pathways required for proliferation
[10,11]. These signaling pathways also converge on NOXs that
produce O2.- and H2O2 (mainly by growth factor receptors). Lipox-
ygenases, which produce lipid hydroperoxides among their pro-
ducts, are stimulated through integrins. Hydroperoxides produced
by these sources stimulate receptor tyrosine kinases and inhibit
protein tyrosine phosphatases, thus sensitizing cells to proliferation
signals [12]. It should be noted that hydroperoxides and not su-
peroxide, hydroxyl or other oxygen centered species function as a
second messenger [13].
b) Even in non-transformed cells a small amount of oxygen is partially
reduced by the mitochondrial electron transport chain resulting in
superoxide production. Cancer cells may utilize a Warburg type
metabolism; i.e., they rely on glycolysis for energy production even
if oxygen is abundant (aerobic glycolysis). It has been proposed that
the Warburg phenomenon aims to spare oxygen for the production
of H2O2 that is used for redox signaling to promote tumor cell
proliferation [14]. It has also been documented that defects in mi-
tochondrial oxidative metabolism, as observed in cancer cells, may
give rise to superoxide, hydrogen peroxide, hydroperoxide produc-
tion and increased glucose utilization aims to provide reducing
equivalents through NADPH and pyruvate necessary for metabo-
lizing hydroperoxides [15,16].
c) Many cells in a tumor mass undergo cell death due to various factors
including insuﬃcient supply of oxygen and nutrients, attack by in-
ﬁltrating cytotoxic immune cells and anti-cancer treatments (che-
motherapy, irradiation and immunotherapy). Cells undergoing
apoptotic or necroptotic cell death overproduce H2O2 due to dis-
ruption of the mitochondrial electron transport system [17].
d) In relation to the previous point, tumor cells undergo repetitive
ischemia-reperfusion cycles due to their irregular blood supply not
always on a par with their ever increasing demand for oxygen and
nutrients as required for rapid growth.
e) The relationship between cancer and inﬂammation is complex. On
the one hand, many (but not all) chronic inﬂammatory conditions
predispose to cancer and, on the other hand, the tumor micro-
environment is also characterized by varying degree of inﬂamma-
tion [18]. Inﬁltrating immune cells produce a plethora of cytokines
and chemokines in the tumor fueling inﬂammation accompanied by
the production of O2.- and hydroperoxides, and species derived from
nitric oxide (NO), including peroxynitrite. NO is produced by nitric
oxide synthases [19], one of which (eNOS/NOS3) is constitutive in
cells and regulated through calcium and kinase signaling, a second
(iNOS/NOS2) is regulated at the level of transcription, and a third
(nNOS/NOS1) is both inducible and signaling regulated. NO is a
well characterized second messenger that activates guanylate cy-
clase [20]. Signaling by peroxynitrite is controversial [21]. While
H2O2, lipid hydroperoxides and NO are involved in signaling, other
species, particularly in the presence of iron freed from proteins, can
cause oxidative damage to macromolecules and disrupt cell in-
tegrity. The inﬂammatory tumor environment promotes tumor
progression by increasing genetic instability, it stimulates metastasis
and may also be involved in therapy resistance [22]. However, ex-
tensive cell death in the inﬂamed tumor environment (especially cell
death involving oxidant-based ER stress, which occurs in response to
certain therapies) may lead to release of tumor antigens. Uptake of
tumor antigens by antigen presenting cells (dendritic cells and
macrophages) results in antitumor adaptive immune responses
(immunogenic cell death).
2. The cancer redox environment
2.1. Sources and types of oxidants in tumors
Oxygen and nitrogen centered oxidants, often called by the vague
terms reactive oxygen and nitrogen species are formed by many cell
types in the tumor microenvironment, including cancer cells, stroma
cells, endothelial cells, innate and adaptive immune cells. As described
above, the main species produced in tumors, as well as normal tissues,
are superoxide, hydrogen peroxide, lipid hydroperoxides, NO and per-
oxynitrite. In tumors, production of these may be greater [23]. All cells
generate O2.- and H2O2 as by-products of mitochondrial ATP generation
in the electron transport chain. In addition, O2.- and H2O2 are produced
in a regulated fashion by the nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidases known as NOX and by the dual oxidases
(DUOX). These families of transmembrane proteins comprise NOX1-5
and DUOX1-2 and their only known function is to produce O2.- and
H2O2, some by one-electron and some by two-electron reduction of
oxygen [8,24–26].
Membrane bound NOXs have been identiﬁed as major sources of
oxidants in cancer. While NOX1 has been implicated mostly in the
regulation of colon cancer cell proliferation, DUOX enzymes have been
linked to the control of epithelial mesenchymal transition (EMT), in-
vasiveness in cancer cell lines (DUOX1) and induction of VEGF and HIF-
1α expression in pancreatic cell lines (DUOX2) [27,28]. NOX2 is, as will
be discussed in a later section, highly expressed in myeloid cells but
may also be expressed at lower levels by other cell types. For example
EBV-infected gastric cancer cells have been shown to express enhanced
NOX2 levels, which contributes to tumor progression [29] and NOX2-
derived radicals have been suggested to contribute to Bim-induced
apoptosis in non-small cell lung cancer cell lines [30]. Recently NOX4
attracted increasing attention. NOX4 was found to localize to the
perinuclear region, nucleus, endoplasmic reticulum, plasma membrane
and also to the mitochondria [31–33]. NOX4 primarily generates H2O2
but mutation of a conserved histidine in its third extracytosolic loop (E-
loop) can switch the protein to a superoxide generating enzyme [34].
The role of NOX4-derived oxidants in cancer is tumor context and
therapeutic modality speciﬁc. For example, in renal cancer cells NOX4
has been found to localize to the mitochondrial inner membrane in an
ATP bound inactive form [35]. NOX4 was activated upon ATP redis-
tribution from mitochondria which led to metabolic reprogramming (a
hallmark of cancer) and resistance to the anticancer drug etoposide.
The underlying mechanism involved NOX4 derived oxidants which
caused inhibition of acetylation-mediated lysosomal degradation of the
“oncogenic” M2 splice variant of pyruvate kinase (PKM2) in etoposide-
treated cells. These data identify NOX4 as a novel energetic sensor
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within the mitochondria, which serves as a checkpoint to couple mi-
tochondrial energy metabolism to drug resistance in cancer cells [35].
Similar tumor promoting role of NOX4 has been reported in breast and
ovarian cancer. These tumors overexpress NOX4 resulting in H2O2-de-
pendent senescence, increased tumorigenicity and etoposide resistance
[33]. The tumor promoting, prosurvival and antiapoptotic role of NOX-
4 which is mediated by Akt kinase activation as demonstrated in pan-
creas adenocarcinoma cells [36,37] may also contribute to therapy
resistance. In contrast, in head and neck cancer cells the EGFR tyrosine
kinase inhibitor Erlotinib caused upregulation of NOX4 and down-
regulation of NOX1,2,5. H2O2 produced by NOX4 was essential for
Erlotinib-induced cancer cell death [38].
Another well examined enzyme that generates O2.- and H2O2 is
xanthine oxidase, which catalyzes the oxidation of hypoxanthine to
xanthine and ultimately to uric acid [39]. There are many other oxi-
doreductases in cells that can produce O2.- and H2O2, but many are
conﬁned to peroxisomes where the catalase concentration is very high.
As mentioned above, nitric oxide is produced by nitric oxide synthase
(NOS) enzymes with NOS2 (inducible NOS) and NOS3 (endothelial
NOS) being the most important sources in tumors. NO can react with
superoxide to form peroxynitrite. The presence of this short-lived and
highly reactive oxidant is evidenced by detection of its footprints ni-
trotyrosine and 8-nitroguanine in proteins and DNA/RNA of tumors,
respectively [40]. The tumor inﬁltrating myeloid cells, such as myeloid
derived suppressor cells (MDSCs) and macrophages often constitute the
major source of oxidizing species generated via the enzymatic systems.
However, in diﬀerent tumors the dominant source, the amount of oxi-
dants produced and the role of these radicals for cancer progression or
destruction may vary. Also, the applied anti-cancer treatments and
antioxidant enzyme expression in the tumor microenvironment may
aﬀect redox status and outcome.
2.2. Redox sensors
While oxidants have been viewed for decades as cell damaging
agents, hydroperoxides and nitric oxide are now widely recognized as
unique signaling molecules. Their signaling role is mediated mostly by
enzymatic oxidation of certain cysteine residues by H2O2 to either
disulﬁdes or mixed disulﬁdes with glutathione resulting in altered
protein structure and functional state [41]. These modiﬁcations are
reversed by specialized reducing proteins glutaredoxins and protein
disulﬁde reductases. For example in non-oxidatively stressed cells, one
of the MAPKKK enzymes named apoptosis signal-regulated kinase 1
(ASK-1) is kept inactive by association with reduced thioredoxin. Upon
formation of a disulﬁde bond in thioredoxin via peroxiredoxin-cata-
lyzed oxidation of two critical cysteines by H2O2, the oxidized thior-
edoxin dissociates from ASK-1 permitting its oligomerization and acti-
vation [42]. H2O2 may also prolong MAP kinase signals by directly
inactivating MAP kinase phosphatases via cysteine oxidation, again
most likely through an enzyme catalyzed process [43]. Similarly, in
growth factor signaling, oxidation of the phosphatase PTEN permits
peptide growth factor (e.g. PDGF or EGF)-induced H2O2 production to
mediate sustained proliferation signals [44].
Induction of certain cellular antioxidant enzyme systems also occurs
via redox signaling mechanisms. The key regulator in this pathway is
Nrf2 (nuclear factor erythroid 2-related factor 2) which is targeted for
degradation via association with KEAP-1 (kelch-like ECH-associated
protein 1). Upon oxidation of key cysteines in KEAP-1, it no longer can
facilitate the ubiquitination of Nrf2 which in turn allows newly syn-
thesized Nrf2 to translocate to the nucleus and bind to EpRE (also
known by the misnomer antioxidant response element, ARE) in the
promoters of antioxidant genes such as glutathione S-transferase, glu-
tathione peroxidase subunits of glutamate-cysteine ligase and NADPH-
quinone oxidoreductase 1 to induce their expression [45].
2.3. Cellular antioxidant systems
Tissue damage caused by excessive production of oxidants is pre-
vented by antioxidant enzymes. In mammals, the former class include
superoxide dismutases (SOD1 and SOD2), catalase, the glutathione
peroxidases (GPx 1–8) and the peroxiredoxins (Prdx 1–6) [46]. SODs
converts superoxide to H2O2 (and O2) while catalase, the glutathione
peroxidases and peroxiredoxins reduce H2O2 to H2O. GPxs and Prdx6
use glutathione as the reducing substrate, Prdxs 1–5 use reduced
thioredoxin, and catalase dismutates H2O2 to H2O and O2.
While all antioxidant enzymes have been linked to various aspects
of cancer biology, SOD2 deserves special attention. On the one hand,
many cancers downregulate SOD2 expression while, on the other hand,
SOD2 overexpression has been shown to suppress tumorigenesis and
cancer cell proliferation with hydrogen peroxide and nitric oxide being
likely eﬀectors [47]. In mouse embryonic ﬁbroblasts the tumor sup-
pressive eﬀect of SIRT3 has been shown to be mediated by SOD2
overexpression pointing towards a role of mitochondrial superoxide in
cell transformation in a single oncogene expression setting [48]. Mi-
tochondrial superoxide also plays a central role in the anticancer eﬀect
of pharmacological ascorbate [49]. Ascorbate selectively induces mo-
bilization of iron from Fe-S clusters and thus increases labile iron pool.
Increased steady state levels of superoxide and H2O2 were commonly
observed in many types of cancer and have also been implicated in the
disruption of homeostatic iron metabolism; a ﬁnding also observed in
tumor cell killing by pharmacological ascorbate. Under this condition
SOD2 increased resistance of tumor cells to ascorbate-mediated cell
killing. In diﬀerent therapeutic settings, where the eﬀects of the DNA
alkylating agent and glutathione reductase inhibitor BCNU (1,3-bis(2-
chloroethyl)-1-nitrosourea) was investigated, higher SOD2 activity was
accompanied by higher toxicity. Combination of SOD2-mediated H2O2
production and impaired H2O2 removal due to glutathione peroxidase
inhibition appeared to be a key factor in this toxicity [47].
In MCF7 cells superoxide was found to stabilize hypoxia inducible
factor-1α (HIF1α), a positive regulator of transcription of genes re-
sponsible for angiogenesis, proliferation, survival and metastasis [50]
and this pathway was inhibited by SOD2 overexpression.
There are thousands of compounds that have antioxidant chemistry
in vitro and appear to have some antioxidant eﬀect in vivo. Scavenging
of oxidants is actually a competition between organic molecules, in-
cluding both small metabolites, vitamins and macromolecules, because
the rate constants for these reactions are usually very close to each
other. For a molecule to be eﬀective as oxidant scavenger in vivo, it
would need to outcompete all other molecules [51]. This simply does
not happen inside of cells except for vitamin E, which is concentrated in
membranes where it reacts with hydroperoxyl radicals. Scavenging of
superoxide, hydrogen peroxide and other hydroperoxides is carried out
eﬃciently by enzyme catalyzed reactions with rate constants that are
100,000 times faster than for the non-enzymatic reactions. Thus, among
the naturally occurring metabolites and vitamins, with the exception of
vitamin E, there is no physiologically meaningful scavenging by non-
enzymatic reactions. The only other signiﬁcant antioxidant eﬀect of
small molecules are chelators that tie up iron so that it cannot catalyze
the production of hydroxyl radical, and inhibitors of NOX, NOS and
other oxidoreductases, as inhibitors of production rather than sca-
vengers of oxidants; e.g., NOX2-inhibitors [52], NOS inhibitors, xan-
thine oxidase inhibitors) or induce antioxidant defenses (e.g. Nrf-2 ac-
tivators) [53]. In cells, the dominant cellular “antioxidant” molecule is
glutathione, which is used by GPxs and Prdx6 rather than as a direct
scavenger of any oxidant.
3. Oxidative stress induced by conventional anticancer therapy
(ionizing radiation, chemotherapeutic agents, PDT)
Conventional anticancer therapy includes the use of chemother-
apeutic agents, radiotherapy or photodynamic therapy. Hydroxyl
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radical and singlet oxygen production are common mechanisms of
many therapeutic approaches for cancers (photodynamic therapy,
radiotherapy, doxorubicin) and is also responsible for many of their
side eﬀects. These approaches involve the production of species that are
associated with damage rather than redox signaling. Of course, damage
itself is recognized by cells and stimulates signaling that may include
redox signaling.
3.1. Radiotherapy
Radiotherapy is given for eliminating tumor cells (curative treat-
ment) or for relieving the symptoms of patients (palliative treatment). It
can be applied internally (with a radioactive material) or externally
(high-energy x-rays at the aﬀected area). Radiotherapy utilizes high-
energy rays and its main cellular target is DNA [54]. Single and double
strand breaks, crosslinks between DNA strands and chromosomal pro-
teins are induced. While electromagnetic radiation ionizes indirectly
through inducing the formation of hydroxyl radicals, heavy particles
such as alpha particles [55] and carbon ions [56] can cause DNA da-
mage directly, hence with higher biological eﬀectiveness. Alpha parti-
cles have relatively short range (≤ 100 µm) resulting in partial tumor
irradiation and limited killing. 223Radium and many other newly de-
veloped alpha emitters may oﬀer the potential for targeted therapy via
conjugation with speciﬁc antibodies or targeted nanoparticles [57].
Carbon ion has quite favorable physical and biological properties for
cancer therapy [56]. It provides a suﬃcient radiation dose to the tumor,
while causing acceptable damage in the surrounding normal tissues.
Adenocarcinoma, adenoid cystic carcinoma, malignant melanoma, he-
patoma, and bone/soft tissue sarcoma respond favorably to carbon ion
radiotherapy. Radiation induces tumor cell death or permanent cell
cycle arrest [58]. It destroys cancer cells, but may also damage normal
cells [59]. However, compared to non-transformed cells, DNA repair in
cancer cells is often defective making them more vulnerable to radio-
therapy.
3.2. Chemotherapy
Classical chemotherapeutics can be classiﬁed as alkylating agents,
antimetabolites, topoisomerase inhibitors and anti-microtubule agents.
3.2.1. Alkylating agents
By deﬁnition, alkylating agents are compounds capable of replacing
a hydrogen atom in another molecule by an alkyl radical. Alkylating
agents (cyclophosphamide, ifosfamide, chlorambucil) can be toxic,
mutagenic, carcinogenic or teratogenic at diﬀerent doses. They de-
crease the rate of cell division, and may cause breakage and other ab-
normalities of chromosomes [60]. Alkylating agents interfere with DNA
replication by crosslinking DNA strands, causing DNA strand breaks and
abnormal base pairing. They tend to be more eﬀective against rapidly
dividing cells. In particular, impairment of replicative ﬁdelity of DNA
during the S-phase could contribute to some of the mitotic and chro-
mosomal eﬀects, as well as to their carcinogenic and teratogenic po-
tencies [60]. The nitrosoureas are a subgroup of the alkylating agents
interfering with DNA replication and repair. Platinum-containing
compounds include agents such as Cisplatin, Carboplatin and Ox-
aliplatin and their cytotoxic properties also extend to alteration of the
cell membrane transport systems and suppression of mitochondrial
function [61]. Cisplatin is used to treat various types of cancers such as
testicular, lung, and ovarian cancers. This drug exhibits multiorgan
toxicity with redox imbalance as a possible mechanism [62,63].
3.2.2. Topoisomerase inhibitors
Topoisomerases I and II can relax DNA supercoiling (e.g. during
replication or transcription) by breaking and rejoining the backbone of
DNA strands. They also play a signiﬁcant role in ﬁxing DNA damage
that occurs as a result of exposure to harmful chemicals or UV rays.
Inhibitors of topoisomerase I (e.g. topotecan, camptothecin) and to-
poisomerase II (e.g. etoposide, doxorubicin) work by binding to the
topoisomerase enzymes and blocking DNA religation after strand
cleavage [64,65].
3.2.3. Anti-microtubule agents
Tubulin proteins form spindle ﬁbers (also called microtubules)
which is essential for cell division. Vinca alkaloids (Vinblastine,
Vincristine) bind to tubulin, inhibiting cytoskeletal dynamics [66].
3.2.4. Antimetabolites
Antimetabolites (methotrexate, 5-ﬂuorourocil and cytosine arabi-
noside) act as analogs of nucleotides interfering with DNA and RNA
synthesis. Most of these agents are speciﬁc for S phase, therefore they
are mostly eﬀective against fast-growing tumors.
3.2.5. Epigenetic reprogrammers
In the pathogenesis of various hematological malignancies (e.g.
myelodysplastic syndrome and diﬀerent forms of leukemias) a critical
event is the silencing of tumor suppressor genes via hypermethylation
of their promoters. The cytosine analogs 5-azacytidine and 5-aza-
2′deoxycytidine (also known as decitabine) can inactivate DNA me-
thyltransferase [67] and can thus restore the activity of suppressed
genes.
3.3. Photodynamic therapy (PDT)
Photodynamic therapy (PDT) utilizes the combination of light and
photosensitizing drugs [68]. When exposed to light with a speciﬁc
wavelength, photosensitizers (e.g. porﬁmer sodium) produce singlet
oxygen. Singlet oxygen is a dienophile that attacks histidine in proteins
and bases in DNA among other targets. The wavelength determines how
far the light can travel into the body. Generally, the light needed to
activate most photosensitizers cannot pass through more than 1 cm. The
photosensitizing agent (given systemically) accumulate in the tumor
cells. The tumor is exposed to the light 24–72 h after the injection,
when most of the drug is eliminated from the normal cells. PDT can act
in two additional ways as well: it can activate the immune system to kill
tumors or it can inhibit the metabolism of the tumors by damaging their
blood vessels. PDT is a local treatment (typically on or just under the
skin) and generally cannot be used to treat metastasized cancer, but can
be combined with other therapies. As laser light can be directed
through optical ﬁbers, it can deliver light to the inside of the body, so
that esophagus or lung cancers can also be treated. Singlet oxygen re-
acts with the polyunsaturated fatty acids of the membranes, producing
lipid hydroperoxides (LOOHs) [69]. The eﬀectiveness of PDT depends
on various factors. The addition of ascorbate and ferrous iron increase
the cytotoxic eﬀect of PDT by further augmenting lipid peroxidation
and the conversion of LOOHs to more cytotoxic species [69]. It was
reported [70] that singlet oxygen generated by photodynamic treat-
ment can inactivate cellular antioxidant enzymes (catalase, SOD1 and
SOD2) in nucleated mammalian cells, which can contribute to cyto-
toxicity. Elevated phospholipid hydroperoxide glutathione peroxidase
(PhGPx) enzyme activity, on the other hand, could contribute to the
resistance of tumor cells to PDT [71].
3.4. Oxidative stress induced by conventional cancer therapy
In radiotherapy and PDT singlet oxygen production is in the very
heart of their mechanism of action (see above). The anthracycline
doxorubicin (Dox) may generate oxidants by more than one me-
chanism [72,73]. Dox itself can be converted by mitochondrial re-
ductases to anthracycline semiquinone free radicals. Under aerobic
conditions, they are able to reduce molecular oxygen to O2.- and H2O2
[74]. Reactions between iron and Dox can also generate hydroxyl ra-
dical through the Fenton reaction. A dose-dependent cardiotoxicity is a
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well-known side eﬀect of Dox therapy and is a major limitation to its
use. Cardiotoxicity is partly caused by doxorubicin-dependent free ra-
dical formation, lipid peroxidation and mitochondrial dysfunction [75].
The alkylating agent cyclophosphamide is widely used to treat
ovarian, breast, and hematological cancers. An adverse eﬀect of cy-
clophosphamide chemotherapy is a reproductive failure and premature
ovarian insuﬃciency. The mechanism that causes the above-mentioned
symptoms includes the markedly increased production of oxidants [76].
The alkylating agent cisplatin is a platinum complex that has been
shown to increase oxidative stress by increasing the levels of superoxide
anion, hydrogen peroxide and hydroxyl radical [62,63]. The topoi-
somerase II inhibitor etoposide (ETO) is a commonly used che-
motherapeutic drug the application of which is limited by its side ef-
fects with the kidney being the most sensitive target where ETO induces
oxidant generation resulting in necrotic cell death [64]. Beta la-
pachone represents a novel anticancer prodrug activated by NAD(P)
H:quinone oxidoreductase 1 (NQO1). NQO1 is overexpressed in many
cancers, making this enzyme ideally suited for intracellular drug acti-
vation [77]. Bioactivation of β-lapachone by NQO1 involves a futile
redox cycle resulting in the release of high amounts of superoxide and
hydrogen peroxide. Oxidant-mediated DNA strand breaks are known to
trigger overactivation of the DNA break sensor enzyme PARP1 [78]
resulting in NAD/ATP depletion and consequent necrotic cell death
[79–82] and the same sequence of events has been observed in β-la-
pachone-treated cancer cells [83]. Combination of β-lapachone with
radiotherapy [84] or with PARP inhibitors has also been reported to be
a synergistic chemotherapeutic modality [85]. In the latter combina-
tion, high amount of oxidants triggered by β-lapachone caused severe
DNA lesions, which were not repaired due to PARP inhibition. PARP
inhibition also converted β-lapachone-induced necrotic cell death to
apoptosis.
Various chemotherapeutic modalities utilize oxidants, which con-
tribute, at least in part, to the elimination of tumors (Table 1). In other
cases, oxidant formation is responsible for the side eﬀects of the
treatments. Sharma et al. detected signiﬁcantly elevated plasma lipid
peroxide and lower antioxidant levels in patients with cervical cancer,
compared to healthy controls [86]. After cisplatin or bleomycin treat-
ment, which was combined with ﬂuorouracil, a relationship was found
between the change in lipid peroxide and antioxidant levels and the
response to the treatment. The therapeutic response could be predicted
by the initial antioxidant levels, and the extent of their change during
the therapy. Also in the case of advanced non-small cell lung cancer
patients, elevated levels of lipid peroxides and NO was detected
(compared to controls) [87,88]. After cisplatin-based combination
chemotherapy, even higher indices of oxidative stress were measured.
Elevation was more evident in higher stage than lower stage patients.
Selenium compounds and other small molecules, some mislabeled
as antioxidants, have anti-cancer eﬀects. Selenium compounds (e.g.
sodium selenite) induce apoptosis in cancer cells, which is mediated by
H2O2 via a mitochondrial-dependent pathway [89]. In drug-sensitive
human tumor cells and in adult male Wistar rats, protective eﬀect of
speciﬁc antioxidant agents (sodium selenite, selenomethionine) was
detected during cytotoxic action of doxorubicin in vitro. In contrast,
there was no protective eﬀect in drug-resistant sublines of these tumor
cells during action of doxorubicin and cisplatin [90]. In the rat model of
squamous cell carcinoma, curcumin not only decreased the survival and
the proliferation of the tumors, but sensitized tumors by targeting
pSTAT3 and Nrf2 pathways [91]. Curcumin protected against the toxic
eﬀect of cisplatin.
Glutathione transferases (GSTs) and TrxR1 are often overexpressed
in tumors and frequently correlated with bad prognosis and resistance
against a number of diﬀerent anticancer drugs. Prodrugs have been
developed that are derivatives of existing anticancer drugs (etoposide,
doxorubicin) incorporating a sulfonamide moiety. With these drugs
GSH levels can be decreased and also the redox regulatory enzyme
thioredoxin reductase 1 (TrxR1) can be inhibited [92]. Synthetic nitric
oxide releasing compounds (e.g. Bifendate (DDB) nitric oxide) are also
eﬀective tools, even in MDR tumors as they are not aﬀected by ABC
transporters. Their eﬀect is based on releasing high amounts of NO in
tumor cells, which causes mitochondrial tyrosine nitration and apop-
tosis. Downregulation of HIF1α, PKB (AKT), ERK and activation of
NFκB was detected in MDR cells [93]. Huang et al. [94] could selec-
tively target cancer cells with estrogen derivatives, which caused
apoptosis in human leukemia cells but not normal lymphocytes. The
selectivity was found to be based on the inhibition of SOD1 and SOD2.
Overproduction of catalase (or application of its analogs) combined
with chemotherapeutic drugs was also found to suppress the pro-
liferation and aggressiveness of lung cancer [95].
Human AP endonuclease is an essential enzyme of base excision
repair, but also acts as a redox signaling factor. Silencing of APE1/Ref1
in A2780 and CP70 cell lines resulted in increased apoptosis [96].
Il'yasova et al. [97] found at least two diﬀerent types of redox
homeostatic mechanisms balancing oxidative stress in humans, which
predispose to drug resistance and toxicities during doxorubicin and
cyclophosphamide chemotherapy.
4. Redox regulation of cancer cell killing by cytotoxic T
lymphocytes and natural killer cells
Tumors that show a dense inﬁltration of immune cells are regarded
as “hot” while tumors containing few immune cells are regarded as
“cold”. In many cancers, the hotter the tumor the better are the pa-
tient´s chances [100–102]. However, the relation between types of in-
ﬁltrating immune cells are of relevance for the outcome. In the ﬁght
against cancer, cytotoxic lymphocytes (CLs) represent the most pow-
erful soldiers in the army of the cellular immune system [103,104]. On
the contrary, tumor inﬁltrating macrophages and myeloid derived
suppressor cells (MDSCs) often represent poor prognostic markers
[104]. Hence, in several cancers, including lung cancer [105], bladder
cancer [106], glioblastoma [107] and renal cell carcinoma [108], a
high ratio between tumor inﬁltrating T cells and myeloid cells prog-
nosticates a favorable outcome [104]. The reason for the negative im-
pact of tumor inﬁltrating myeloid cells is assumed to be the suppressive
factors, including oxidants that are produced by myeloid cells and in-
hibit the cytotoxic functions of CLs. However, all myeloid cell inﬁltrates
are not disadvantages. As discussed in more detail below certain types
of macrophages may inhibit tumor growth and dendritic cells that also
represent a myeloid cell type are necessary for proper tumor-speciﬁc T
cell responses to evolve.
In the following section, we will summarize how the tumor redox
environment aﬀect CL-mediated killing of cancer cells. Though cyto-
toxic lymphocytes are sensitive to excessive levels of oxidants that
trigger inactivation and apoptosis, low levels of oxidants are needed for
the lymphocytes to exert their cytotoxic functions.
4.1. CL-induced cytotoxicity is accompanied by oxidant production
CD8 positive cytotoxic T lymphocytes (CTLs) express T cell re-
ceptors (TCRs) and recognize tumor antigen peptides associated with
MHC-I (major histocompatibility type I) cell surface proteins (Fig. 1).
Thus CTL-mediated tumor cell killing is antigen-speciﬁc and requires
expression of MHC-I proteins by the tumor cells. Natural killer (NK)
cells, on the other hand, are more eﬀective against cancer cells with
defective expression of MHC-I molecules. Hence, recognition of tumor
cells by NK cells does not require the presentation of antigens on MHC-
I, but instead the NK cells interact with a wide range of activating and
inhibitory receptors such as the natural cytotoxicity receptors (NCRs),
killer immunoglobulin-like receptors (KIR), C-type lectin receptors and
immunoglobulin like transcripts (ILT) (Fig. 1) [109]. Since NK cells
express Fc receptors (recognizing the invariable Fc region of im-
munoglobulins) they can also bind tumor cells via tumor-bound anti-
bodies (e.g. therapeutic antibodies such as anti-EGFR or anti-Her Ab)
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Table 1
Oxidants and antioxidants in chemotherapy. Chemotherapeutics often utilize oxidants, which may contribute to the elimination of tumors. In other cases, oxidant formation is
responsible for the side eﬀects of the treatments.
Tumor model/context In vitro or in
vivo
Finding
Chemotherapeutic agents induce oxidants, alter antioxidant systems
cervical cancer, 5-ﬂuorouracil, followed by cisplatin and bleomycin in vivo, human The alterations in the circulating pro/antioxidants in advanced cervical cancer
patients were investigated, before and after neoadjuvant chemotherapy. The
pretreatment levels of “antioxidants” and oxidants and also the extent of their
change during treatment can predict the therapeutic response to neoadjuvant
chemoradiation in advanced cervix cancer [86].
lung cancer, cisplatin in vivo, human Oxidative stress was detected after cisplatin based combination chemotherapy
induced in NSCLC patients. The pretreatment levels of LPO and NO in NSCLC
patients were signiﬁcantly higher while GSH and SOD were signiﬁcantly lower,
compared to control. A higher elevation of oxidative stress was detected after
the chemotherapy and was more evident in higher stage than lower stage
patients [87].
non-small cell lung cancer patients, cisplatin + etoposide in vivo, human Oxidative stress markers (LPO and NO) and antioxidant levels (GSH and SOD)
were investigated in control and in NSCLC patients, before and after cisplatin +
etoposide combination chemotherapy. In responders LPO and NO were low
while GSH and SOD were high [88].
keratinocyte apoptosis, Doxorubicin Mitochondrial superoxide in vitro (HaCaT) Doxorubicin induces keratinocyte apoptosis. Mitochondrial superoxide can
mediate the apoptotic process through the oxidative modiﬁcation of ERK and
Bcl2 ubiquitination [98].
human NSCLC (non-small cell lung cancer) cell lines, MCF-7 cells, A549
cells, MDA-MB triple negative breast cancer cells, MiaPaCa2
ortothopic xenografts
in vitro and in
vivo (mice)
β-lapachone undergo redox cycling-dependent bioactivation by NAD(P)
H:quinone oxidoreductase 1 (NQO1) which is accompanied by H2O2 production.
Subsequent DNA breakage and PARP1 activation depletes NAD+/ATP pools
culminating in necrotic cell death. Combination of β-lapachone with the PARP
inhibitor rucaparib cause synergistic cell death by apoptosis [85].
Non-traditional treatments for the elimination of cancer cells that utilize oxidative stress
prostate cancer, Sodium selenite in vitro Human prostate cancer cells were treated with sodium selenite. Upon treatment,
mitochondrial-dependent superoxide production was detected, that was at least
partly responsible for the induction of apoptosis [89].
MDR cancer cells, NO in vitro Bifendate (DDB) nitric oxide, a synthetic nitric oxide releasing compound,
eﬀectively decreased viability of both sensitive and MDR tumor cells. The
proposed mechanism includes mitochondrial tyrosine nitration and apoptosis on
the one hand, and HIF1α downregulation and the phosphorylation (activation)
of PKB (AKT), ERK, and NFκB in MDR cells on the other hand [93].
Intervention with endogenous antioxidant systems enhance tumor killing by chemotherapeutic agents
doxorubicin, selenium compounds, and D-pantethine in vitro and in
vivo study
Protective eﬀect of speciﬁc agents (sodium selenite, selenomethionine, D-
pantethine) during cytotoxic action of doxorubicin was demonstrated in vitro in
drug-sensitive human tumor cells and in adult male Wistar rats. In contrast, was
no protective eﬀect could be detected in drug-resistant sublines [90].
Glutathione transferase overexpressing cancer cells, doxorubicin
derivatives
in vitro GSTs are often overexpressed and TrxR1 is often upregulated in tumors and
frequently correlated to bad prognosis and resistance against a number of
diﬀerent anticancer drugs. These cells could be selectively targeted with drug
derivatives, incorporating a sulfonamide moiety (ANS-etoposide, ANS-DOX)
[92].
head and neck squamous cell carcinoma, rat model of cisplatin-induced
ototoxicity, cisplatin, curcumin
in vitro, in vivo Cisplatin has an ototoxic side eﬀect. The modulating eﬀect of curcumin was
investigated in the rat model of cisplatin-induced ototoxicity, and in head and
neck squamous cell carcinoma cells. Curcumin attenuated all stages of tumor
progression (survival, proliferation) and, by targeting pSTAT3 and Nrf2
signaling pathways, curcumin sensitized cells to cisplatin in vitro and protected
from its ototoxic adverse eﬀects in vivo [91].
human leukemia cells, SOD, selective tumor killing in vitro Certain estrogen derivatives selectively kill human leukemia cells but not
normal lymphocytes. Superoxide dismutase (SOD) was identiﬁed as a target of
this drug action and show that chemical modiﬁcations at the second carbon (2-
OH, 2-OCH3) of the derivatives are essential for SOD inhibition and for apoptosis
induction [94].
lung cancer cells, catalase, cisplatin chemotherapy in vitro In lung cancer cells, combining Catalase (or CAT analogs) with traditional
chemotherapeutic drugs, especially cisplatin, was found to be a promising
therapeutic strategy. The overexpression of the antioxidant enzyme catalase
(CAT) might control tumor proliferation and aggressiveness [95].
A2780 and CP70 cell lines, platinum based chemotherapy APE1/Ref1
inhibitor
in vitro In patients not responding to platinum based chemotherapy, altered levels and
subcellular distribution of APE1/Ref1 expression was found comparing with
those who responded to platinum based chemotherapy. In A2780 and CP70 cell
lines APE1/Ref1 silencing resulted in increased apoptosis after platinum based
chemotherapy [96].
breast cancer patients, urine samples, Doxorubicin, Cyclophosphamide
chemotherapy
in vivo, human Urine samples of breast cancer patients show, that there are diﬀerences in the
redox homeostatic control between cancer patients. These diﬀerences may
underlie predisposition to drug resistance and toxicities. There may be at least
two distinct redox phenotypes with diﬀerent homeostatic mechanisms balancing
oxidative stress in humans [97].
human head and neck cancer cells (FaDu cells) in vitro If combined with cisplatin, 2-deoxy-glucose increases the steady-state levels of
H2O2 and enhances the disruption in thiol metabolism, leading to increased
oxidative stress and increased cell killing [99].
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resulting in ADCC (antibody-dependent cell-mediated cytotoxicity)
[110]. Thus, ADCC is of special importance for antibody-based cancer
immunotherapies.
Although NK cells and CD8+ CTL cells recognize target cells
through diﬀerent receptors and operate diﬀerent activation pathways,
their eﬀector functions are basically identical. One of the most potent
cytotoxic mechanisms of CLs (cytotoxic lymphocytes: CTLs and NK
cells) is mediated by perforins [111]. In resting CLs perforin is localized
to the cytotoxic granules and upon activation it is released by exocy-
tosis. Secreted perforin undergoes calcium dependent polymerization to
form cylindrical pores of 5–20 nm in the target cell membrane. Ac-
cording to the widely held but experimentally not fully proven view,
the other powerful weapons of CLs, granzymes can enter cancer cells
through these pores. Alternatively, granzymes can also enter target cells
through mannose-6-phosphate receptors or via electrostatic linkage to
the target cell membrane [112]. Once inside the tumor cells, the serine
protease granzymes unleash apoptotic and non-apoptotic cell death
pathways [113].
Both CTLs and NK cells utilize cell surface death ligands to induce
programmed cell death in the target cells [114]. These death ligands
include FAS-ligand, TRAIL (TNF-related apoptosis-inducing ligand),
TNFα and they act through death receptors belonging to the TNF re-
ceptor superfamily.
Oxidants have a dual role in the regulation of CTL and NK cell
function. Evans et al. [115] modelled CL-mediated cytotoxicity by
treating breast cancer cells with the combination of the membrane
damaging, pore forming protein streptolysine O (to mimic perforin) and
granzyme B and reported oxidant production accompanying cancer cell
death (Table 2). The crucial role of oxidants in cancer cell killing or
sensitization was indicated by the observation that expression of the
antiapoptotic XIAP protein (which rendered tumor cells resistant to
PBMC-induced ADCC) suppressed oxidation of the dye, 2',7'-di-
chlorodihydroﬂuorescein (DCFH). Oxidation of DCFH is often, although
falsely, thought to be a measure of H2O2 production [116]. Never-
theless, DCFH oxidation often correlates with oxidative stress.
The inhibitory eﬀect of MnTBAP, which scavenges both O2.- and
H2O2, on ADCC reaction provided further support for the active role of
oxidants in CL-mediated cancer cell destruction [115]. A possible me-
chanism underlying the sensitizing eﬀect of oxidants to CL-mediated
killing of cancer cell may be the upregulation of NK cell activating
molecules on the surface of cancer cells. In multiple myeloma cells,
subtoxic concentrations of melphalan or doxorubicin induced the DNA
damage response (DDR) and caused cell senescence [117]. Senescent
myeloma cells upregulated ligands (MICA, MICB and PVR) for NK cell
activating receptors NKG2D and DNAM1 in an oxidant-dependent
manner resulting in enhanced NK cell activation [118].
4.2. Eﬀects of tumor-associated inﬂammatory stress and therapy-induced
oxidant production on CLs
The relationship between cancer and inﬂammation is complex
[119]. It has been well established that inﬂammation is a common
feature of most solid tumors. Chronic inﬂammation has a predominant
role in tumor survival and proliferation, angiogenesis and im-
munosuppression [120]. As detailed above, cancer cells also produce
H2O2 and use it for proliferation signaling. Moreover, conventional
cancer therapy with chemotherapeutic agents, ionizing radiation,
photodynamic treatments or therapeutic antibodies are all known to
induce oxidant production [62,64,68,72]. But, it is important to re-
member that low level production of H2O2 is involved in enzyme-cat-
alyzed redox signaling, while production of high levels of H2O2 or
production of hydroxyl radicals by radiation or singlet oxidation in
photodynamic therapy causes indiscriminant damage. Also therapeutic
antibodies, such as the anti-CD20 antibody rituximab that is used in the
treatment of chronic lymphoid leukemia (CLL), triggers oxidant pro-
duction by interacting with the Fc-receptor of myeloid cells [121]. The
myeloid derived oxidants decrease the capacity of NK cells to exert
ADCC against antibody bound tumor-cells. Treatment with NOX2-in-
hibitors or H2O2 scavengers restored the NK cell-mediated ADCC ac-
tivity in cocultures between CLL cells, NK cells and monocytes [121].
On a similar note, CTLs equipped with engineered T cell receptors
(CAR-T cells = chimeric antigen receptor-redirected T cells) that co-
expressed catalase were protected from hydrogen peroxide stress and
maintained high tumor killing activity indicating that hydrogen per-
oxide contributes to T cell anergy [122].
While performing their tasks, CLs are constantly exposed to oxidants
and strategies to reduce the oxidative stress have been proposed to
enhance the ability of CLs to kill tumor cells. However, activated CLs
may partly adapt to the oxidatively stressed tumor environment by
upregulating antioxidant proteins (e.g. peroxiredoxin 1 and thioredoxin
1) as demonstrated with IL-2-activated NK cells [123]. Also, DCs have
been shown to provide antigen-speciﬁc T cells with antioxidative thiols
during antigen presentation, which made them more resistant to oxi-
dant-induced apoptosis [124].
The inﬂammatory and redox environment may diﬀer signiﬁcantly
between individual tumors and between diﬀerent parts of the same
tumor mass. In general, macrophages and MDSCs play a central role in
creating an inﬂammatory environment in the tumors (see below), that
other tumor-inﬁltrating lymphocytes such as CTLs and NK cells are also
exposed to and have to cope with. One of the suppressive features of
macrophages and MDSCs is the production of O2.- and H2O2 via the
NADPH oxidase NOX2. The NOX2 enzyme is highly expressed in cells of
the myeloid linage, such as monocytes/macrophages and neutrophils
[125]. While NOX2-derived H2O2 is critical for these cells to eliminate
microbes during infections, the high localized concentration of H2O2
Fig. 1. Tumor cell recognition by NK cells and CTLs: regulation by MΦs and MDSCs.
CD8 positive cytotoxic T lymphocytes (CTLs) express T cell receptors (TCRs) and re-
cognize tumor antigen peptides associated with MHC-I cell surface proteins. NK cells
interact with a wide range of activating and inhibitory receptors such as the natural
cytotoxicity receptors (NCRs), KIR (killer immunoglobulin-like receptors), C-type lectin
receptors and immunoglobulin like transcripts (ILT). Since NK cells express Fc receptors
(recognizing the invariable Fc region of immunoglobulins) they can also bind tumor cells
via tumor-bound antibodies (e.g. therapeutic antibodies such as anti-EGFR or anti-Her
Ab). Tumor-associated macrophages and myeloid-derived suppressor cells (MDSC) exert
suppressive eﬀects on both T cells and NK cells. NOX2, eNOS and iNOS are key players in
the production of superoxide, hydrogen peroxide, NO and ONOO- (The small spherical
objects inside NK and T cells represent lytic granules which serve to store cytotoxic
proteins.).
C. Hegedűs et al. Redox Biology 16 (2018) 59–74
65
that may be achieved via NOX2 has also been linked to im-
munosuppression in cancer [126–128]. Hence, in a conﬁned in-
ﬂammatory site, NOX2-derived H2O2 triggers dysfunction and apop-
tosis of adjacent cytotoxic lymphocytes, including cytotoxic T cells and
NK cells [126–129]. Genetic disruption of Nox2 has in mouse models
been shown to reduce melanoma metastasis formation by protecting
tumor killing NK cells from oxidant-induced inactivation [52]. Also
Nox2-/- mice showed a reduced growth rate of subcutanous melanoma
and lung carcinoma, but sarcoma growth and prostate cancer growth
were not aﬀected [130,131]. Pharmacological inhibition of NOX2 by
histamine dihydrochloride (HDC) is, together with low doses of IL-2,
utilized as a relapse-preventive strategy for acute myeloid leukemia
(AML) patients in complete remission [132,133]. The proposed me-
chanism of action for HDC is to protect anti-leukemic lymphocytes from
oxidant-induced inactivation and thereby restoring their responsiveness
to IL-2 [133].
MDSC can phenotypically be divided into granulocytic (G-MDSC)
and monocytic (Mo-MDSC) subgroups. Both subgroups utilize redox
Table 2
Redox regulation of the antitumor functions of natural killer cells, cytotoxic T lymphocytes and lymphokine-activated killer cells. Oxidants may be produced and may even
contribute to perforin and granzyme B-induced cancer cell killing. On the other hand, tumor-associated inﬂammatory stress and therapy-induced oxidant production may compromise the
tumor killing eﬀect of CLs.
NK/CTL/LAK Tumor model/context In vitro/vivo Findings
human NK triple combination therapy with bortezomib,
oHSV, and NK cells
in vitro human and
in vivo mouse
xenograft
• Combination treatment with bortezomib and oHSV, induced
necroptotic cell death and increased the mitochondrial H2O2 and
JNK phosphorylation production.
• RIPK1 and JNK inhibitors/shRNA rescued synergistic cell killing.• Combination treatment also signiﬁcantly enhanced NK cell
activation and adjuvant NK cell therapy of mice treated with
bortezomib and oHSV improved antitumor eﬃcacy [139].
human NK myelogenous leukemia/general cell mechanism/
oxidative stress
in vitro human • IL-2 NK and expanded NK are more resistant to H2O2 than resting
NK
• PRDX1 and TXN1 are upregulated in activated NK cells• IL-2 confers protection on NK cells against oxidative stress mainly by
up-regulation of TXN1 [123]
human NK human melanoma/NK cells in vitro human • During NK-mediated tumor cell killing two High Mobility Group
Box-1 (HMGB1) forms are released, each displaying a speciﬁc
electrophoretic mobility possibly corresponding to a diﬀerent
redox status.
• In NK/melanoma cell co-cultures, NK cells speciﬁcally release an
HMGB1 form that acts as chemoattractant, while dying tumor cells
passively release a non-chemotactic HMGB1 [140].
primary NK MCF7 (breast cancer), A549 (lung carcinoma),
MDA-MB-231 (breast adeno carcinoma), U937
(monocytic leukemia)
in vitro human • IR (ionizing radiation) induced an increase in expression of MICA/
MICB (MHC class I-related chain molecules A and B) in MCF7 cells
• SFN induced MICA/MICB expression in A549 and MDA-MB-231
cells and increased susceptibility to NK cell-mediated killing [141].
transduced T cells/NK cells Her2+ SkoV3 cells and Her2-speciﬁc CAR-
transduced T cells
in vitro human • CAR-CAT T cells (Chimeric Antigen Receptor coexpressing
catalase) protect in trans both T and NK cells from oxidative
stress–mediated repression.
• CAR-CAT T cells display an increased inhibition of intrinsic oxidant
production upon T cell activation
• CAR-CAT T cells maintain their activity under H2O2 stress• CAR-CAT T cells mediate a protective bystander eﬀect [122].
K562 (Human myeloid leukemia cell line) were
used as targets for NK cells
Human CD3-/CD56+ NK
cells
chronic lymphocytic leukemia (CLL) CD14+
monocytes
in vitro human • Inhibitors of oxidant formation preserved NK cell viability and
restored NK cell-mediated ADCC [121].
CD8+ Cytotoxic
T lymphocytes (CTL)
nanogels for cancer vaccine delivery to dendritic
cells (DC)
in vivo human • Nanoparticle-triggered lysosome rupture could directly induce
oxidant production in DCs, which was found to be essential for
augmenting proteasome activity and downstream MHC I antigen
presentation [142].
Cytotoxic T lymphocytes
(CTL)
HLA-A2+ human melanoma CTL homeostasis in vitro human • Superoxide production increases upon TCR (T-cell receptor)
stimulation with the cognate epitope
• Inhibition of oxidant production rescues CTL from AICD (Activation-
induced cell death) without impairing their eﬀector functions
• Antigen-reactive primary CTL and TIL (tumor inﬁltrating
lymphocytes) escaped AICD when treated with MnTBAP (SOD and
catalase mimic) [143]
PBMC human in vitro human • Treatment with ox-LDL induced a signiﬁcant down-regulation of
proliferative response to mitogens, antigens and interleukin-2 in
PBMC.
• NK cell-mediated cytotoxic activity was signiﬁcantly down-
regulated by ox-LDL while treatment with N-acetylcysteine (NAC), a
precursor for cysteine used in glutathione biosynthesis, induced a
signiﬁcant up-regulation of NK-cell activity.
• Ox-LDL and NAC exerted opposite eﬀects on the cytokine network
[144]
Activated PBMC parental IBC cell lines Inﬂammatory breast cancer
(IBC)
in vitro human • XIAP inhibit caspase activity which results in ADCC resistance• resistance was dependent on XIAP-mediated, caspase-independent
suppression of oxidant production
• the anti-apoptotic function-mediated by binding caspases and/or the
caspase-independent oxidant-suppressive function [115]
HER2 resistance
mature plasma cells (PCs) in
BM
chemotherapeutic stress on cancer cells promote
antitumor immune responses in MM (multiple
myeloma) cells
in vitro human • Oxidant- dependent activation of the DDR (DNA damage
response) pathway is involved in NKG2D and DNAM-1 genotoxic
drug-induced ligand upregulation on senescent MM cells [117].
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mechanism to cause T cell unresponsiveness or T cell apoptosis, and are
reportedly more suppressive compared to granulocytes and monocytes
from healthy subjects [134]. Granulocytic MDSC produce peroxynitrite
(via combination of NOX2-derived superoxide and eNOS-derived NO)
to induce T cell unresponsiveness (due to nitration-mediated T cell
receptor inactivation) and T cell apoptosis [135–137]. Monocytic MDSC
express iNOS, generate NO but their T cell suppressing eﬀect doesn’t
appear to require peroxynitrite formation and may be due to a direct
eﬀect of NO [137,138].
5. Redox regulation of interactions between cancer cells and
macrophages
5.1. Tumor associated macrophages: enemies within or potential anticancer
weapons?
Macrophages (MΦ-s) are part of the innate immune system and
together with monocytes and dendritic cells they comprise the mono-
nuclear phagocyte system. While in most organs, tissue resident mac-
rophages populate the organs prenatally, in the gut and skin circulating
blood monocytes signiﬁcantly contribute to the macrophage pool
[145,146]. Under inﬂammatory conditions, however, circulating
monocytes can also enter most tissue niches and diﬀerentiate to mac-
rophages upon exposure to CSF1 (M-CSF) and GM-CSF [147].
Macrophages are also among the ﬁrst host cells inﬁltrating the
tumor mass [119]. But their role in the tumor environment is a classic
case of a double-edged sword situation. On the one hand, MΦ-s have
the potential to kill cancer cells. However, the presence and high
number of MΦ-s in the tumor tissue is widely recognized as a negative
prognostic marker. This is especially true in breast, head and neck,
mesothelium, thyroid, liver, pancreas, kidney, bladder, ovarian, uterus,
and cervix cancer as well as in glioma, melanoma and non-Hodgkin
lymphoma while in colorectal cancer, high macrophage density was
correlated with increased patient survival [148]. Thus the question
arises whether macrophage-induced tumor killing is only an in vitro
phenomenon which is not relevant in tumors or the cytotoxic activity of
MΦ-s is “real” but suppressed in tumors.
Traditionally MΦ-s have been viewed as cells capable of destroying
cancer cells. Macrophages activated in vitro with interferon gamma,
LPS, glycans etc. display tumor cell killing activity. Although unlike T
cells, MΦ-s are not equipped with speciﬁc antigen recognition re-
ceptors, they are still capable of binding to tumor cells (Fig. 2). To
recognize cancer cells MΦ-s utilize – among other molecules - calreti-
culin binding receptors [149]. In damaged tumor cells (e.g. after che-
motherapy), the ER protein calreticulin translocates to the plasma
membrane [150] where it can bind to the MΦ-s cell surface protein
CD91. Other tumor-derived DAMPs (damage-associated molecular
patterns) such as ATP, HMGB1, nucleic acids also activate MΦ-s via
diﬀerent TLRs (HMGB1 and nucleic acids) [151] and purinoceptor
P2X7R (ATP) [152]. MΦ-s can phagocytose bound tumor cells. In ad-
dition to calreticulin-CD91 interactions, cancer cell phagocytosis by
macrophages is also facilitated by opsonization of cancer cells by an-
tibodies (e.g. therapeutic antibodies such as Herceptin). ADCP (anti-
body-dependent cancer cell phagocytosis) leads to processing and pre-
sentation of tumor-derived antigens triggering antitumor T cell
responses and thus lays the foundation for the adaptive immune re-
sponse [153].
Despite possessing a wide array of potentially cytotoxic mechan-
isms, MΦ-s appear to be one of tumors’ best friends. Recruitment of
monocytes to cancer is mediated by tumor-derived chemokines (e.g.
CCL2) and cytokines (CSF-1) [154]. Depending on the composition of
the MΦ-s environment, MΦ-s may exist in many functional states. Al-
though these polarization pathways most likely represent a continuous
spectrum, they are often characterized by the extremes of these con-
tinuums: i.e. M1 and M2 MΦ-s [155]. IFNγ and TNFα stimulate po-
larization towards M1 (inﬂammatory) MΦ-s, while IL4 and IL13 (and
tumor-derived CCL2, CSF1 and IL10) initiate M2 polarization (Fig. 3)
[156]. (Markers of M1 and M2 MΦ-s diﬀer greatly between human and
mouse and are summarized in [157].) M1 macrophages produce O2.-,
H2O2, and NO and the cytotoxic cytokine TNFα and can thus keep
tumor cells under control. However, due to exposure to IL4, IL13 and
IL10, the typical phenotype of TAMs (tumor-associated macrophages) is
M2, often referred to as anti-inﬂammatory, remodeling or “wound
healing” MΦ-s. M2 cells express T cell inhibitory PD-L1 and produce T
cell suppressing mediators (TGFβ, and PGE2) [158]. Thus, the role of
MΦ-s in the tumor microenvironment is to mediate immunosuppression
and thus protect cancer cells from attack by cytotoxic eﬀector cells
[159]. In certain cancer types (e.g. melanoma, colorectal and gastric
cancer), however, MΦ polarization is skewed towards the M1 state and
inﬁltration of these tumors with MΦ-s is recognized as a positive
prognostic marker [160–162].
MΦ
Tumor cell
Fig. 2. Recognition of tumor-associated molecular patterns by macrophages.
Surface bound antibodies, externalized calreticulin or released nucleic acids or ATP can
modify macrophage phenotype via interactions with speciﬁc cell surface receptors.
Fig. 3. Macrophage polarization. Exposure of M0 macrophages to IL-4, IL-13 and IL-10
induces diﬀerentiation towards the M2 phenotype. Stimulation by LPS and IFNγ induces
M1 polarization. While M2 macrophages promote cancer cell growth, M1 macrophages
are potentially cytotoxic to cancer cells.
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5.2. Redox control mechanisms of MΦ-tumor cell interactions
The encounter of MΦ-s and cancer cells may involve antibody-de-
pendent cellular phagocytosis/trogocytosis and consequent cytotoxicity
(ADCP and ADCC, respectively). MΦ-s utilize their cell surface Fc re-
ceptors to bind tumor associated antibodies (e.g. produced by the hu-
moral anti-tumor immune response or administered to the patient as a
therapeutic antibody). This step can be followed by phagocytosis of the
tumor cells (ADCP) [163] or MΦ-s biting out pieces of the tumor cells’
plasma membrane (trogocytosis) [164]. The outcome of antibody-
mediated MΦ responses against tumor cells can lead to tumor cell de-
struction (ADCC) via production of cytolytic proteases, oxidants or
TNFα [165].
MΦs are prototypical O2.-, H2O2, and NO producing cells and oxi-
dants represent one of the most potent weapons of activated MΦ-s in
the combat against cancer [166,167]. While monocytes preferentially
produce O2.- and H2O2, MΦ-s predominantly use peroxynitrite [168] for
in vitro tumor killing. Monocytes and MΦ-s operate NADPH oxidase
(NOX) enzymes for superoxide production. NOX2, the dominant NOX in
MΦ-s is a multisubunit protein and its components are localized in the
cell membrane as well as in the cytosol. Various signals [167] can lead
to NOX2 activation which requires translocation of the cytosolic sub-
units (p47phox, p67phox and Rac1) to the cell membrane where they
associate with the membrane localized NOX2 components (gp91, p21)
to form the functional holoenzyme [169]. Critical steps in the signaling
cascade leading to NOX2 activation include elevated cytosolic calcium
concentrations, activation of PKCα and cPLA and production of ara-
chidonic acid with the latter inducing membrane translocation of cy-
tosolic subunits [170].
Activated MΦs express iNOS via an NFκB-mediated pathway [171].
iNOS derived NO can combine with superoxide to form the cytotoxic
product peroxynitrite (ONOO-). While NO is not considered as a cyto-
toxic mediator against cancer cells, rather it stimulates tumor cell
proliferation, extravasation and metastasis formation, peroxynitrite on
the other hand is a potent cytotoxic molecule with the potential to
destroy any cells.
The question arises whether any of the MΦs antitumor eﬀector
functions are under redox control (Table 3). The early phases of MΦ-
tumor cell interactions (i.e. ADCP and trogocytosis) appear to lack any
signiﬁcant redox control mechanism. It has been shown for example
that intrasplenically injected melanoma and colon carcinoma cells are
taken up rapidly by MΦs (Kupﬀer cells) via high aﬃnity FcgRI and low
aﬃnity FcgRIV without any involvement of oxidants [172]. Opsoniza-
tion of tumor cells by antibodies (e.g. anti-CD47) not only stimulates
ADCP but it also induces a shift from M2 to M1 and results in slower
tumor progression and prolonged survival of the animals [173]. Al-
though the role of oxidants was not directly assessed in this study, the
M2 to M1 shift was likely accompanied by increased oxidant producing
potential of the reprogrammed MΦs. This hypothesis is supported by
other studies documenting MΦ reprogramming (e.g. by gold or silver
nanoparticles [174] or heme oxygenase-derived carbon monoxide and
these studies demonstrated a requirement for oxidants for the shift to
M1 state.
Numerous studies have addressed the role of oxidants in the tumor-
killing eﬀect of MΦs. For example pigment epithelium derived factor
(PEDF) stimulated not only migration of macrophages into tumor
spheroids, but phagocytosis and oxidant-mediated apoptotic killing of
cancer cells [175]. Moreover, a synthetic analogue of 15-epi-lipotoxin
A4 reprogrammed macrophages from M2 to M1 like phenotype and
reprogrammed cells expressed iNOS, produced O2.- via NADPH oxidase,
and thus inhibited cancer growth [176]. Furthermore, GSH depletion
caused an increased H2O2 half-life and inhibition of tumor progression
[177]. These data collectively indicate that modulations of macrophage
phenotype that tip the balance between oxidants and the capacity to
remove them in favor of the oxidants eﬃciently suppress cancer pro-
gression both in vitro and in vivo.
On the other hand, a substantial body of ﬁndings questions the role
of oxidants in tumor control. Several studies suggested that NOX1/2-
derived superoxide or non-speciﬁed oxidants promote M2 polarization
and cancer progression [178,179]. H2O2 production by macrophages or
myeloid cells has also been shown to fuel tumor progression via driving
angiogenesis, promoting cancer cell proliferation, inhibition of mir328
and blocking diﬀerentiation of DCs and MΦs [180]. Radiotherapy has
also been shown to stimulate invasion and metastasis formation via
oxidants (and H2O2-induced CXCR4 expression) [181].
6. Therapeutic considerations
Oxidants play a multifaceted and highly complex role in tumor
biology. Tremendous eﬀorts have been made to take advantage of in-
tratumoral redox imbalance and turn it against cancer. The controversy
surrounding the role of oxidants in cancer is exempliﬁed by the often
opposite therapeutic approaches put forward by scientists. While some
of these approaches stimulate oxidant production, others were based on
the use of antioxidants or NOX2 inhibitors [121]. Despite some limited
success, a common feature of these opposite approaches is that they all
failed to provide an answer to the questions:
a) Why accelerating oxidant production or using antioxidant therapies
work in some instances but fail in others?
b) How can we predict which type of redox-based therapy might pro-
vide therapeutic beneﬁt?
In order to resolve these controversies surrounding redox therapies
of cancer, one must ﬁrst appreciate the complexity of the problem with
special recognition to be given to the facts that
a) Tumors cannot be viewed as a single disease as diﬀerent cancer
types diﬀer greatly in the way they form, what drives their growth,
invasion and metastasis and what type of redox dysregulation they
display.
b) Tumors cannot be viewed as a mass of highly proliferating trans-
formed cells as the tumor stroma (including regulatory and eﬀector
immune cells) plays a fundamental role in the behavior of tumor
cells and their responses to chemotherapy, immunotherapy and
redox therapy.
c) Oxidants are not equal and the term reactive oxygen species is in-
accurate and misleading. The chemical identity of the produced
oxidants, as well as compartmentalization and kinetics of oxidant
production need to be given careful consideration.
d) The role of oxidants should be determined individually in every
tumor to decide if it is a oxidant-driven cancer or a non oxidant
driven cancer.
e) Immunosurveillance need to be taken into account [118]. Oxidant-
induced immunosuppression of CLs promote tumor growth. The
relative importance of this phenomenon relates to the content of
tumor-inﬁltrating leukocytes and the sensitivity of the tumor cells to
immune-mediated clearance.
f) Molecules referred to as antioxidants do not function eﬃciently as
scavengers of free radicals or other oxidants, but may induce anti-
oxidant enzymes, or be used as a precursor of cysteine used for
glutathione biosynthesis (N-acetylcysteine in particular), or have
other eﬀects on signaling that counters the eﬀects of oxidants.
A detailed redox characterization and classiﬁcation of tumors in-
cluding antioxidant enzymes expression, cell signaling and transcrip-
tion factor activation proﬁles need to be established to identify whether
and how a speciﬁc type of cancer can be targeted by redox-based
therapies [191]. Attempts to compile such a combinational set of pre-
dictive cellular parameters have already been made [97] and we should
continue and broaden such eﬀorts.
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Table 3
Role of oxidants and antioxidants in the regulation of MΦ-mediated cancer cell killing. Depending on the model systems used, studies either report A) lack of eﬀects of certain
oxidants in MΦ's eﬀector cell functions; B) demonstrate the active role of oxidants in mediating MΦ –induced cancer cell killing or C) regulate MΦ function in a way favoring cancer cell
survival.
Macrophage Tumor model/context In vitro or in vivo Finding
Lack of eﬀect of oxidants in some MΦ eﬀector functions
Kupﬀer cells Mouse B16F10 melanoma cells and C26 colon carcinoma
cells injected intrasplenically in mice
in vitro/in vivo • Kupﬀer cells eﬀectively arrest and phagocyte intact
tumor cells after antitumor mAb treatment
• Phagocytosis is dependent on FcγRI and FcγRIV.• Antibody-dependent phagocytosis is not aﬀected by
reactive oxygen or nitrogen species production [172].
Human PBMC-derived MΦ
and murine BM-derived
MΦ
Glioblastoma (GBM) cells, mouse xenograft model in vitro/in vivo • Following anti-CD47 treatment, both M1 and M2
macrophages displayed increased tumor cell
phagocytosis rates in vitro (higher rates by M1).
• Anti-CD47 treatment In vivo changed the macrophage
polarization proﬁle toward anti-tumorigenic
microenvironment (increased the ratio of M1
macrophages) [173].
Kupﬀer cells Metastases model in Wag/Rij rats (CC531s tumor cell line
injected to mesenteric vein)
in vivo • Tumor speciﬁc monoclonal antibody prevents liver
metastases from colorectal cancer.
• Antibody-dependent phagocytosis is the main mechanism.• Kupﬀer cells are the main eﬀector cells in eliminating
tumor cells [182].
Oxidants promote MΦ-mediated cancer cell killing
RAW264.7 Lung adenocarcinoma mice (Kras model), A549 xenograft
models
in vivo • Exogenous CO at low doses blocks progression of lung
cancer.
• The eﬀects of CO are mediated by H2O2-dependent
activation of MAPK/Erk1/2 - c-myc pathway as well as
Notch 1-dependent negative feedback on the metabolic
enzyme heme oxygenase-1 (HO-1).
• CO treatment modulates macrophage phenotype and
alters macrophage function to anti-tumoral [183].
BMDM
tumor associated
macrophages (TAMs)
Murine ﬁbrosarcoma induced 3-methylcholanthrene (MCA) in vitro • Gold and silver nanoparticles increase the production of
O2-, H2O2 and NO in tumor-associated macrophages.
• High oxidant production is associated with a suppressed
antioxidant enzyme system, resulting in a shift of TAMs
from M2 (pro- tumorigenic) to M1 (anti-tumorigenic)
nature [174].
WT, HIF-1α KO, and HIF-2α
KO mouse MΦ
Mouse model of breast cancer in vivo model,
mathematical model
• The model and experimental data predict that tumor-
associated macrophages, speciﬁcally through HIF-1α
activity, can augment tumor intracellular GSH to help
tumor cells develop resistance to therapy.
• Tumors with HIF-1α deﬁcient macrophages grow slower
and have reduced levels of intracellular GSH.
• GSH depletion can raise the rate of production of oxidants
above a toxic threshold and result in inhibition of tumor
growth [177].
RAW264.7, THP-1, BMDM Mouse and human tumor cell lines in vitro • Pigment Epithelium-Derived Factor (PEDF) stimulates
the migration of macrophages towards tumor 3D
spheroids and 2D cultures.
• PEDF induces the phagocytosis of tumor cells through an
indirect apoptosis-dependent mechanism.
• PEDF increases superoxide production by macrophages.• Conditioned media from PEDF-treated macrophages
induces apoptosis, suggesting that oxidants may be
involved in tumor cells apoptosis.
• PEDF-mediated signaling involves PNPLA2 up-regulation
on macrophages to induce M1 polarization and CD47
down-regulation on tumor cells which in collaboration
with ATP5B elevation on macrophages leads to
phagocytosis [175].
Human peripheral blood
mononuclear cells
(PBMC)
MV3 human melanoma cells, murine melanoma model
(subcutaneous injection with B16F10 melanoma cells)
in vitro/in vivo • ATL-1, a synthetic analogue of 15-epi-lipoxin A4, could
modulate TAM activity proﬁle.
• ATL-1 selectively decreased M2 surface markers in TAM,
induces NO production by increasing the iNOS/arginase
ratio and activated NADPH oxidase, triggering H2O2
production.
• ATL-1 inhibits tumor progression in a murine model in
vivo [176].
Tumor-associated
macrophages
MCF-10A and A549 cell lines, mouse xenograft model in vitro/in vivo • Oncogenic MCT-1 (multiple copies in T-cell malignancy
1) activity promotes oxidant generation.
• Overexpression of MCT-1 elevates MnSOD level via the
YY1-EGFR signaling cascade, which protects cells against
oxidative damage [184].
(continued on next page)
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Table 3 (continued)
Macrophage Tumor model/context In vitro or in vivo Finding
Oxidants inhibit MΦ-mediated cancer cell killing
Human peripheral blood
mononuclear cells
(PBMC)
CAFs isolated from pancreatic tumor, Human pancreatic
cancer cell line Panc1 and Miapaca2
in vitro • Pancreatic cancer-associated ﬁbroblasts (CAFs) induce a
tumor-promoting TAM phenotype in monocytes
• Secreted M-CSF from CAFs led to enhanced H2O2
production and M2 polarization in monocytes [185].
Bone marrow-derived MΦ,
Resident peritoneal MΦ
Mouse Xenograft Models (LLC cells) in vivo/in vitro • NOX1 and NOX2 are critical for the diﬀerentiation of
monocytes to macrophages, the polarization of M2-type
but not M1-type macrophages, and the occurrence of
tumor-associated macrophages (TAMs).
• Decrease in M2 macrophages and TAMs contributes to the
delay in wound healing and the inhibition of tumor
growth and metastasis in NOX1/2 double knockout mice
[178].
– NSCLC H1299 cells, H1299 xenografts in nude mice, lung
cancer tissues from patients
in vitro/in vivo • Radiotherapy can promote the invasion and metastasis
of several types of cancer.
• After irradiation, hypoxia-inducible factor 1α (HIF-1α)
was increased and translocated into the nucleus and
promoted the transcription of CXCR4.
• Oxidants also play a role in the radiation-induced
expression of CXCR4.
• NAC reduce the transcriptional activation of CXCR4
promoter by 2 Gy irradiation [181].
MDSCs (myeloid-derived
suppressor cells)
Subcutaneous tumor models in mice: DA3 mammary
carcinoma, CT26 colon carcinoma, MethA sarcoma, EL4
thymoma, Lewis lung carcinoma, MC38 colon carcinoma,
C3 sarcoma.
in vivo • Oxidant production is up-regulated in myeloid-derived
suppressor cells (MDSC) in seven diﬀerent tumor
models and in cancer patients.
• Increased production of O2- and H2O2 in MDSCs is
regulated by NADPH oxidase-2 (NOX2).
• MDSCs from NOX2 deﬁcient mice lost the ability to
suppress T cell responses and quickly diﬀerentiated into
mature macrophages and dendritic cells [126].
Mouse peritoneal
macrophages
Blood samples of head and neck cancer patients
Macrophages (and DCs,
granulocytes)
Mouse tumor models (CT-26 colon carcinoma and C3
sarcoma)
in vitro/in vivo • Diﬀerentiation of ImC (immature myeloid cells from
tumor-bearing mice was signiﬁcantly delayed.
• Rates of oxidant production were signiﬁcantly higher in
ImC from tumor-bearing mice. Hydrogen peroxide but not
superoxide was found to be the major part of increased
oxidant production.
• ImC transferred into tumor-bearing recipients failed to
diﬀerentiate into DC or macrophages [186].
ImC (immature myeloid
cells)
C3 ﬁbrosarcoma in vitro (ex vivo) • ImC (immature myeloid cells) generated in tumor-
bearing hosts suppress the CD8+ T cell response via
production of oxidants.
• Interaction of ImC with Ag-speciﬁc T cells in the presence
of speciﬁc Ag-s resulted in a signiﬁcant increase in oxidant
production.
• The increase in oxidant production was mediated by
integrins [187].
murine TAMs (tumor-
associated
macrophages)
C26 murine colon carcinoma cells in vitro • TAMs have anti-inﬂammatory and pro-angiogenic
eﬀects on C26 tumor cells.
• Inhibition of NADPH oxidase in macrophages reduced the
production of angiogenic proteins.
• The stimulatory eﬀects of TAMs on C26 cell proliferation
may be related mainly to their pro-oxidant actions exerted
by NADPH oxidase activity, which maintains the redox
status and the angiogenic capacity of the tumor
microenvironment [188].
Human and mouse
monocytes and
macrophages
Mouse tumor models: in vitro/in vivo • O2.- and H2O2 production is critical for macrophage
diﬀerentiation and inhibition of superoxide production
speciﬁcally blocks the diﬀerentiation of M2
macrophages [179].
Urethane model, Kras model, Breast tumor model
THP-1 macrophages Human gastrointestinal cancer cell lines, human gastric
carcinoma tissue samples
in vitro • Oxidative stress by M1 and M2 macrophages induced
downregulation of miR-328 and upregulation of CD44
• CD44 is a direct target of miR-328.• Increased CD44 expression results in tumor progression by
enhancing antioxidant defense [180].
Tumor-associated
macrophages
MCF-10A and A549 cell lines, mouse xenograft model in vitro/in vivo • Oncogenic MCT-1 (multiple copies in T-cell malignancy
1) activity promotes oxidant generation.
• Overexpression of MCT-1 elevates MnSOD level via the
YY1-EGFR signaling cascade, which protects cells against
oxidative damage [184].
(continued on next page)
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